C

Cencora

Distributes medicines and supports patient care

Product Owner Cold Chain Monitoring

Full-TimePosted on 10/22/2026
No salary listed
Senior
London, UK+1 moreMore locations: Madrid, Spain
HybridHybrid working is based in Madrid or London.
ProductProduct Management

About the job

Requirements
  • At least 5 years of experience in product ownership or product management, with a strong track record in agile environments.
  • Experience owning a roadmap and prioritising a backlog for digital products or services, and writing business requirements and acceptance criteria.
  • Experience working with IT development teams on system integrations across several platforms.
  • Strong stakeholder management and the ability to influence without formal authority in a global, matrixed organisation.
  • An analytical mindset and the ability to use data and key performance indicators to prioritise and measure outcomes.
  • Comfort working across cultures and time zones.
  • English proficiency at C1 level or higher, written and spoken.
Responsibilities
  • Own and prioritise the roadmap and backlog for the monitoring digital products, including the Temperature Monitor Selection capability, real-time temperature and location monitoring services, and the monitoring integration and automation backlog.
  • Own the Temperature Monitor Selection capability, including device selection by packaging type, temperature range and customer requirements, selection logic, user workflow, data-source alignment and product direction; support standardised monitor selection across the network.
  • Own the improvement backlog for the real-time temperature and location monitoring services, including adoption, service performance, report generation time and success rate, customer visibility and integration reliability.
  • Prioritise fixes for missing real-time temperature and location monitoring URLs and other integration failures caused by ghost ship units, previous device assignments, incomplete shipment closure, improper shipment creation and monitor-status issues.
  • Define business requirements and acceptance criteria for monitoring-related changes across TMS, X-Act, Customer Portal, Digital Control Tower, eMDM and downstream systems.
  • Work with IT development teams on integrations and updates to TMS, X-Act, Digital Control Tower and Customer Portal, ensuring delivery stays aligned with priorities.
  • Support the digital enablement of monitor ship units, including monitor type, temperature range, pricing, real-time temperature and location monitoring functionality, reporting and Customer Portal visibility.
  • Advance automated shipment creation, report generation and delivery, alerting and customer communications to reduce manual handling.
  • Work with Operations and Customer Service to validate monitoring workflows, gather feedback and improve usability.
  • Work with QA, Cold Chain Packaging, Procurement, Packaging Fleet Management and vendors when enablement depends on qualification, documentation, pricing, ship units, device onboarding or system readiness.
  • Partner with the Product Owners for Digital Control Tower and Cold Chain Intelligence on proactive shipment management and dashboard strategy.
Desired Qualifications
  • Knowledge of logistics systems such as TMS, customer portals, or IoT and real-time tracking solutions.
  • Experience in regulated industries such as pharma, healthcare or logistics.
  • Agile or product certifications such as CSPO or SAFe PO, or similar.
  • Additional languages.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.